TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30624128

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 610

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Cross-over from Leuprolide to Degarelix
Number of subjects: 610
Study: 26968970

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study: 24127687

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22820612

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor-based regimen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (7 individuals)
Number of subjects: 16
Study: 19561150

Group type: EXPERIMENTAL
Intervention: Post-dilution haemodiafiltration (HDF)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 19
Study: 17227324

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 815

Group type: COMPARATOR
Intervention: Oral medication treatment
Number of subjects: 815

Group type: COMPARATOR
Intervention: Diet only treatment
Number of subjects: 815
Study: 14997947

Group type: EXPERIMENTAL
Intervention: Discussion of sport psychology and its personal benefits
Number of subjects: 124

Group type: COMPARATOR
Intervention: Discussion of sports experiences
Number of subjects: 124
Study: 11722955

Group type: EXPERIMENTAL
Intervention: 14 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 22 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20
Study: 9393425

Group type: EXPERIMENTAL
Intervention: Bone quality types 1 and 4
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Bone quality type 2
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Bone quality type 3
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Anterior mandible
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Posterior mandible
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Anterior and posterior jaw regions
Number of subjects: 2839
Study: 8204277

Group type: EXPERIMENTAL
Intervention: Sucralfate cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Base cream
Number of subjects: 50
Study: 3117165

Group type: EXPERIMENTAL
Intervention: Continuous 4 metric polydioxanone (PDX); 374 patients
Number of subjects: 757

Group type: COMPARATOR
Intervention: Continuous 4 metric polypropylene (PPL); 383 patients
Number of subjects: 757
Study: 31279749

Group type: EXPERIMENTAL
Intervention: G8 screening followed by comprehensive geriatric assessment (CGA) and multidisciplinary team conference
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard assessment based on oncologist's clinical judgement (control)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 96
Study: 29861263

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation plus Kinesio Taping (SM + KT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (SM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (SM + KT)
Number of subjects: 42
Study: 26696251

Group type: EXPERIMENTAL
Intervention: Single-dose rabbit anti-thymocyte globulin (SD-rATG) 6 mg/kg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Divided-dose rabbit anti-thymocyte globulin (DD-rATG) 1.5 mg/kg/dose
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both SD-rATG and DD-rATG
Number of subjects: 95
Study: 25616646

Group type: EXPERIMENTAL
Intervention: 6 months of clopidogrel
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: 12 months of clopidogrel
Number of subjects: 4000
Study: 23673440

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 36
Study: 20550020

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 34
Study: 18086798

Group type: EXPERIMENTAL
Intervention: Rituximab plus CHVP-I
Number of subjects: 194

Group type: COMPARATOR
Intervention: CHVP-I
Number of subjects: 194
Study: 15684166

Group type: COMPARATOR
Intervention: 50 microg of sublingual misoprostol
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 100 microg of sublingual misoprostol
Number of subjects: 212
Study: 12851519

Group type: COMPARATOR
Intervention: HRT (n = 43)
Number of subjects: 127

Group type: COMPARATOR
Intervention: PL (equivalent to 100 mg isoflavone; n = 45)
Number of subjects: 127

Group type: COMPARATOR
Intervention: PL (n = 45)
Number of subjects: 127
Study: 10566461

Group type: EXPERIMENTAL
Intervention: Online vaccine reminders
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no reminders)
Number of subjects: 2
Study: 9093647

Group type: EXPERIMENTAL
Intervention: Xylocaine 10% spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silkospray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endosgel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 1910697

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (4 mg/kg of 4% lidocaine)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 133
Study: 6293259

Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and irradiation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Irradiation
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Preoperative treatment (irradiation)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Primarily operated patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Patients operated upon after preoperative treatment
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Size of the residual tumour and tumor grade
Number of subjects: 153
Study: 30789387

Group type: EXPERIMENTAL
Intervention: Percutaneous Drainage (PCD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Peritoneal Lavage (PL)
Number of subjects: 86
Study: 29377951

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 80
Study: 26967236

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of less than 120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of less than 140 mm Hg)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 9361
Study: 24112099

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Healthy Eating diet
Number of subjects: 120
Study: 22313522

Group type: EXPERIMENTAL
Intervention: Carrot juice (Study 1)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Spinach powder (Study 1)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin supplements (Study 2)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (Study 2)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin-rich foods
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin supplements
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline MPL (both studies)
Number of subjects: 127
Study: 19962805

Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (HDF)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 493
Study: 17386108

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: RPA class I
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: RPA class II
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: RPA class III
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Higher Karnofsky Performance Status (KPS)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Neurosurgery
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Single metastases
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Brain metastases score (BS-BM)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Control of primary tumor
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Absence of extracranial metastases
Number of subjects: 174
Study: 14752633

Group type: EXPERIMENTAL
Intervention: LapSim
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Box trainer
Number of subjects: 24

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LapSim vs Box trainer
Number of subjects: 24
Study: 11523609

Group type: EXPERIMENTAL
Intervention: 2.5 V amplitude at 0.4 ms pulse duration (for DDD pacemakers)
Number of subjects: 305

Group type: COMPARATOR
Intervention: 3.5 V amplitude at 0.4 ms pulse duration (for DDD pacemakers)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: 2.5 V amplitude at 0.4 ms pulse duration (for VVI pacemakers)
Number of subjects: 305

Group type: COMPARATOR
Intervention: 3.5 V amplitude at 0.4 ms pulse duration (for VVI pacemakers)
Number of subjects: 305
Study: 9796839

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 7532882

Group type: EXPERIMENTAL
Intervention: Simulator (Group S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional (Group T)
Number of subjects: 40
Study: 3137634

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30832554

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 123
Study: 31578925

Group type: EXPERIMENTAL
Intervention: Neurodynamic sliding technique (3 × 20 reps)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Static stretching protocol (3 × 30")
Number of subjects: 50
Study: 28488230

Group type: EXPERIMENTAL
Intervention: Pictorial warnings proposed by FDA
Number of subjects: 244

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Warnings proposed by FDA with additional text
Number of subjects: 244
Study: 27704562

Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg single oral dose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg co-administered with Efavirenz 600 mg
Number of subjects: 21
Study: 24044461

Group type: EXPERIMENTAL
Intervention: Implants placed 3 months after augmentation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Implants placed 6 months after augmentation
Number of subjects: 14
Study: 23082392

Group type: EXPERIMENTAL
Intervention: Test dentifrice (stannous‐containing sodium fluoride with high cleaning silica and polychelation technology)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Positive control dentifrice (currently marketed whitening dentifrice with ADA Seal of Acceptance)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between test dentifrice and positive control dentifrice
Number of subjects: 120
Study: 19522571

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 16 mg/kg intravenously every day for 3 days
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 18546838

Group type: EXPERIMENTAL
Intervention: Epithalamin pineal gland peptide medication
Number of subjects: 0
Study: 15793365

Group type: COMPARATOR
Intervention: Genotypic resistance testing alone (G arm)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Genotypic plus phenotypic testing (G + P arm)
Number of subjects: 311
Study: 12418499

Group type: EXPERIMENTAL
Intervention: 1600 mg SAMe/d orally for 6 weeks
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: 400 mg SAMe/d intramuscularly for 4 weeks
Number of subjects: 431

Group type: COMPARATOR
Intervention: 150 mg imipramine/d orally
Number of subjects: 431
Study: 10386277

Group type: EXPERIMENTAL
Intervention: MedEJet
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Biojector
Number of subjects: 75

Group type: COMPARATOR
Intervention: Needle administration
Number of subjects: 75
Study: 8876913

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole abdominal irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation alone in medically inoperable patients
Number of subjects: 0
Study: 1882649

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 6641536

Group type: EXPERIMENTAL
Intervention: 120 mg gentamycin intramuscularly
Number of subjects: 65

Group type: COMPARATOR
Intervention: 3 g amoxicillin orally
Number of subjects: 65
Study: 30928207

Group type: EXPERIMENTAL
Intervention: Real-rTMS (cerebellar low-frequency rTMS, 1200 stimulations per day for 5 days at 90% of resting motor threshold, 1-Hz frequency)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham-rTMS (sham treatment)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Real-rTMS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 22
Study: 28697858

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No irradiation
Number of subjects: 79
Study: 26362661

Group type: EXPERIMENTAL
Intervention: 20g SQ-LNS with 5mg zinc
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: 20g SQ-LNS with 10mg zinc
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: 20g SQ-LNS without zinc and 5mg zinc tablet
Number of subjects: 2435

Group type: COMPARATOR
Intervention: 20g SQ-LNS without zinc and placebo tablet
Number of subjects: 2435
Study: 25271116

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 61
Study: 22406056

Group type: EXPERIMENTAL
Intervention: CoStar paclitaxel‐eluting stent (PES)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Taxus paclitaxel‐eluting stent (PES)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Multiple CoStar stenting
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Multiple Taxus stenting
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Single stenting (both CoStar and Taxus)
Number of subjects: 238
Study: 20848367

Group type: EXPERIMENTAL
Intervention: F1 (most flexible)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: F3 (biomimetic ankle-foot roll-over shape)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: F4
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: F5 (least flexible)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: F2
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oxygen cost (mL O(2)/kg/m)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Order of use
Number of subjects: 13
Study: 17984403

Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride (20 mg/d) with CBT
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo with CBT
Number of subjects: 126
Study: 15771764

Group type: EXPERIMENTAL
Intervention: LAM (lansoprazole 30 mg b.d., amoxicillin 1 g b.d., metronidazole 400 mg t.d.s.)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: LAC (lansoprazole 30 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d.)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: RMT (ranitidine bismuth citrate 400 mg b.d., metronidazole 400 mg t.d.s., tetracycline 500 mg q.d.s.)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: LAM
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: LAC
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 342
Study: 12473020

Group type: EXPERIMENTAL
Intervention: DNR order present
Number of subjects: 241
Study: 9617511

Group type: EXPERIMENTAL
Intervention: Lisuride (0.3 mg daily for 12 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7650167

Group type: EXPERIMENTAL
Intervention: Trypanosoma cruzi epimastigote ribosomal fraction ELISA
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (patients without Chagas' disease)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: RNP ELISA
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Western blot assay
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: IgG isotype distribution
Number of subjects: 216
Study: 3297874

Group type: EXPERIMENTAL
Intervention: BCG immunostimulation
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control (cytostatic drugs and/or surgery without BCG)
Number of subjects: 147
Study: 30358728

Group type: EXPERIMENTAL
Intervention: Daily oral conjugated equine estrogens (0.625 mg/d)
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 27457964

Group type: EXPERIMENTAL
Intervention: Orteronel 300 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 25137428

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Anastrozole (1 mg)
Number of subjects: 39
Study: 22784212

Group type: EXPERIMENTAL
Intervention: Qigong exercise program (6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham Qigong exercise program (6 weeks)
Number of subjects: 14
Study: 20133511

Group type: EXPERIMENTAL
Intervention: Oral treprostinil 1 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination of oral treprostinil 1 mg twice daily and bosentan 125 mg twice daily
Number of subjects: 24
Study: 18675689

Group type: EXPERIMENTAL
Intervention: H pylori eradication regimen (lansoprazole 30 mg twice daily, amoxicillin 750 mg twice daily, and clarithromycin 200 mg twice daily for a week)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Standard care (no treatment for H pylori)
Number of subjects: 544
Study: 18448418

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg (P150) with ibuprofen 800 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg (P75) with ibuprofen 800 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diazepam 5 mg (D5) with ibuprofen 800 mg
Number of subjects: 90
Study: 15034644

Group type: EXPERIMENTAL
Intervention: Vitamin A intake (0.53 mg/day)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Highest 5% vitamin A intake
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Vitamin A intake
Number of subjects: 2016
Study: 11399694

Group type: EXPERIMENTAL
Intervention: Active group (n = 36) participated in a 6-week program of education (2 h weekly) and exercise (1 h weekly)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (n = 29) reviewed routinely as medical outpatients
Number of subjects: 65

Group type: COMPARATOR
Intervention: Active group vs Control group at 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Active group vs Control group at 24 weeks
Number of subjects: 65
Study: 9295454

Group type: EXPERIMENTAL
Intervention: Off-the-shelf orthopedic footwear
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 8369010

Group type: EXPERIMENTAL
Intervention: Ferro‐Folsan (100 mg of ferrous‐II‐sulfate and 0.85 mg of folic acid)
Number of subjects: 14
Study: 3737298

Group type: COMPARATOR
Intervention: Formula samples given at discharge from the hospital
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Maternal factors (age, education, nonsmoking, previous breast-feeding, planned pregnancy, initiation of breast-feeding in the first 16 hours, minimization of formula supplementation)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Partial breast-feeding (supplementing more than one bottle of formula per day)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Frequent nursing (seven or more times per day) despite formula supplementation
Number of subjects: 166
Study: 28277441

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with implantation of an intraocular lens
Number of subjects: 21
Study: 29771077

Group type: EXPERIMENTAL
Intervention: Flupentixol melitracen (1 tablet/day) for 3 months
Number of subjects: 163

Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 163
Study: 26503843

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 60
Study: 24491199

Group type: EXPERIMENTAL
Intervention: Mindfulness treatment group (MTG)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 91
Study: 22144668

Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogen sulfate (CHS) 75 mg/d
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clopidogrel besylate (CB) 75 mg/d
Number of subjects: 86
Study: 20666753

Group type: EXPERIMENTAL
Intervention: Er:YAG laser with water cooling
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with water cooling
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Er:YAG laser without water cooling
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser without water cooling
Number of subjects: 28
Study: 17989536

Group type: EXPERIMENTAL
Intervention: Venom immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid protocols for venom immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venom immunotherapy in patients with mast cell diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New strategies for venom immunotherapy (genetic engineering)
Number of subjects: 0
Study: 15370157

Group type: EXPERIMENTAL
Intervention: Urine immunoassay test strips (ITS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Gas chromatography/mass spectrometry (GC/MS)
Number of subjects: 236